- Home
- VNT vs VKTX Comparison
VNT vs VKTX Comparison
Compare VNT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNT | VKTX |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VNT | VKTX |
|---|---|---|
| Price | $32.33 | $33.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $46.89 | ★ $95.86 |
| AVG Volume (30 Days) | 1.6M | ★ 1.9M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 0.36 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $3,075,600,000.00 | N/A |
| Revenue This Year | $2.39 | N/A |
| Revenue Next Year | $4.19 | N/A |
| P/E Ratio | $38.19 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $27.25 | $22.96 |
| 52 Week High | $48.20 | $43.15 |
Technical Indicators
Market Signals| Indicator | VNT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 45.25 |
| Support Level | $27.72 | $30.10 |
| Resistance Level | $37.60 | $35.37 |
| Average True Range (ATR) | 1.09 | 1.34 |
| MACD | -0.17 | -0.04 |
| Stochastic Oscillator | 21.28 | 65.19 |
Price Performance
Historical ComparisonAbout VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2025.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.